Related Experiment Video
Updated: Jun 1, 2026
11:34
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
siRNAs: potential therapeutic agents against hepatitis C virus
Usman A Ashfaq1, Muhammad Z Yousaf, Maida Aslam
1Division of Molecular Medicine, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan. usmancemb@gmail.com
Virology Journal
|June 8, 2011
Summary
Hepatitis C virus (HCV) treatments are limited. RNA interference (RNAi) using small interfering RNAs (siRNAs) offers a promising alternative therapy by degrading viral RNA, potentially combined with host gene targeting for improved efficacy.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
- Therapeutics
Background:
- Hepatitis C virus (HCV) causes chronic liver disease, liver cancer, and death.
- Current interferon and ribavirin therapy has limited efficacy, especially for common genotypes 1a and 2a, and causes adverse effects.
- Existing treatments are insufficient for widespread HCV eradication.
Purpose of the Study:
- To review the potential of RNA interference (RNAi) as an alternative therapeutic strategy for Hepatitis C virus.
- To evaluate the efficacy of small interfering RNAs (siRNAs) in inhibiting HCV replication.
- To explore the benefits of combining siRNAs targeting both viral and host genes for enhanced HCV treatment.
Main Methods:
- Review of existing scientific literature on RNA interference and HCV.
- Analysis of studies reporting the use of synthetic and vector-based siRNAs against HCV.
- Evaluation of combination therapy approaches using siRNAs targeting viral and host factors.
Main Results:
- RNA interference (RNAi) demonstrates efficient and specific inhibition of HCV replication.
- Both synthetic and vector-based siRNAs show promise in preclinical studies.
- Combination therapy with siRNAs targeting multiple viral and host genes may overcome resistance and improve treatment outcomes.
Conclusions:
- RNA interference (RNAi) represents a potent and specific therapeutic approach for Hepatitis C virus.
- Combining siRNAs targeting viral and host genes is a promising strategy to enhance treatment efficacy and overcome limitations of current therapies.
- Further research into combination RNAi therapies could lead to more effective treatments for chronic Hepatitis C.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...